Agios Pharmaceuticals
Tracked across 3 events · 18 articles · First seen Apr 23, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Agios is the central company seeking FDA approval for mitapivat in sickle cell disease; the priority review is a major catalyst, with shares rising over 12%.
Jul 07, 2026 · 6 articles
Regulatory
Agios Pharmaceuticals announced on July 21, 2026 that its Phase 2 trial of tebapivat for sickle cell disease failed to demonstrate sufficient differentiation, leading the company to discontinue development of the drug in that indication.…
Impact: Agios is the subject of the investigation and the company that discontinued tebapivat development, causing a stock price drop. The investigation could result in legal and financial repercussions.
Jul 28, 2026 · 6 articles
Business
Impact: Orlando Oliveira previously held senior leadership roles at Agios Pharmaceuticals.
Apr 23, 2026 · 6 articles
100
Agios Pharmaceuticals discontinued developmentAgios tebapivat trial...
80
Pomerantz LLP launched investigation Agios PharmaceuticalsAgios tebapivat trial...
ERGEN INTELLIGENCE
Track Agios Pharmaceuticals live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard